Author

Y. Anami

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

K. Tsuchikama· 3 shared A. Yamaguchi· 2 shared N. Zhang· 2 shared W. Xiong· 2 shared Y. Otani· 2 shared Z. An· 2 shared A. Azhdarinia· 1 shared B. Kaur· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

K. Tsuchikama

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer

J. Jacob, Y. Anami, P. High, Z. Liang, S. Subramanian, S. C. Ghosh, S. AghaAmiri, C. Guernsey-Biddle, H. Tran, J. H. Rowe, A. Azhdarinia, K. Tsuchikama, K. S. Carmon

This study develops and tests EREG-targeting ADCs showing efficacy in both RAS mutant and wildtype CRC, with high potency and safety in preclinical models.

bioRxiv · Feb 20, 2024 · PreprintCancer Biology

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors

Y. Anami, Y. Otani, W. Xiong, S. Y. Y. Ha, A. Yamaguchi, N. Zhang, Z. An, B. Kaur, K. Tsuchikama

This study shows that homogeneous antibody-drug conjugates (ADCs) improve therapeutic efficacy in glioblastoma models compared to heterogeneous ADCs.

bioRxiv · Dec 23, 2021Bioengineering

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance

C. M. Yamazaki, A. Yamaguchi, Y. Anami, W. Xiong, Y. Otani, J. Lee, N. T. Ueno, N. Zhang, Z. An, K. Tsuchikama

This study develops dual-payload antibody-drug conjugates to overcome breast tumor heterogeneity and drug resistance, showing improved efficacy in a xenograft model.

bioRxiv · Dec 18, 2020Bioengineering